Previous 10 | Next 10 |
Investment thesis With the recent launch of Liquid Biopsy, China expansion, machine learning platform later in the year and a slight pivot to attempting to sell population sequencing to more countries, Personalis has become an even more enticing opportunity. Developments since IPO O...
Building a genomics platform isn't easy. To gain insights into mysteries of biology, any "-omics" platform needs volumes of data that would have been impossible to obtain, let alone process, just a decade ago. But gaining access to the right biobank can make all the difference and significantly ...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that company management will participate in the 1-on-1 meetings at the upcoming Needham Virtual Cancer Diagnostics 1x1 Conference on Tuesday, August 18, 2020. About Personalis, Inc. Personali...
Shares of Personalis (NASDAQ: PSNL) fell nearly 14% today, after the company announced the pricing of a public offering of common stock. The genomics company will issue up to 7.56 million shares of common stock at $19 apiece. The offering could result in gross proceeds of up to $143.5 millio...
Staffing 360 Solutions (NASDAQ: STAF ) -21% on Q2 earnings . More news on: Staffing 360 Solutions, Inc., Jumia Technologies AG, Super League Gaming, Inc., Stocks on the move, , Read more ...
Personalis (NASDAQ: PSNL ) has priced its public offering of 6,578,947 common stock at $19/share, for expected gross proceeds of $125M . More news on: Personalis, Inc., Healthcare stocks news, , Read more ...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced the pricing of its previously announced underwritten public offering of 6,578,947 shares of its common stock at a price to the public of $19.00 per share. Gross proceeds to Per...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced that it has commenced an underwritten public offering of $100 million of its common stock. In addition, Personalis expects the underwriters to be granted a 30-day option to pur...
Personalis, Inc. (PSNL) Q2 2020 Earnings Conference Call August 6, 2020 5:00 PM ET Company Participants Caroline Corner – Investor Relations John West – President and Chief Executive Officer Aaron Tachibana – Chief Financial Officer Conference Call Partici...
Personalis (NASDAQ: PSNL ) : Q2 GAAP EPS of -$0.29 beats by $0.05 . More news on: Personalis, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its second quarter 2024 financial results on Wednesday, August 7, 2024. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific...
A look at the top 10 most actives in the United States Serve Robotics Inc. (SERV) rose 187.1% to $7.55 on volume of 255,453,115 shares 60 Degrees Pharmaceuticals Inc. (SXTP) rose 10.2% to $0.271 on volume of 224,640,171 shares NVIDIA Corporation (NVDA) fell 2.6% to $117.93 on volume of 21...
SALT LAKE CITY and FREMONT, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc. (Nasdaq: PSNL) today announced that they have entered into an agreement to cross-license patent estates covering tum...